Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
QL1706 + nab-paclitaxel + cisplatin
- Development stage
- Phase 2
- Lead developer
- Qilu Pharmaceutical
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
QL1706 + nab-paclitaxel + cisplatin is a combination chemo-immunotherapy regimen being evaluated for the first-line treatment of advanced or metastatic esophageal squamous cell carcinoma (ESCC). The regimen consists of QL1706, a novel bifunctional antibody developed by Qilu Pharmaceutical that simultaneously targets the PD-1 and CTLA-4 immune checkpoints, combined with the cytotoxic agents nab-paclitaxel (an albumin-bound microtubule inhibitor) and cisplatin (a platinum-based DNA cross-linking agent). By combining dual checkpoint blockade with standard chemotherapy, the regimen aims to enhance anti-tumor immune responses and improve clinical outcomes. A Phase 2 clinical trial (NCT05614323) sponsored by The First Affiliated Hospital of Henan University of Science and Technology is currently investigating the efficacy and safety of this combination in patients with ESCC.
- Other names
- QL1706 plus nab-paclitaxel and cisplatinQL-1706 plus nab-paclitaxel and cisplatinQL 1706 plus nab-paclitaxel and cisplatinQL1706 + albumin-bound paclitaxel + cisplatin
02
Targets
CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)DNAPDCD1 (Programmed cell death protein 1 receptor)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on QL1706 + nab-paclitaxel + cisplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on QL1706 + nab-paclitaxel + cisplatin.